Probiotic preparation VSL#3 induces remission in children with mild to moderate acute ulcerative colitis: A pilot study
Article first published online: 9 DEC 2008
Copyright © 2008 Crohn's & Colitis Foundation of America, Inc.
Inflammatory Bowel Diseases
Volume 15, Issue 5, pages 760–768, May 2009
How to Cite
Huynh, H. Q., deBruyn, J., Guan, L., Diaz, H., Li, M., Girgis, S., Turner, J., Fedorak, R. and Madsen, K. (2009), Probiotic preparation VSL#3 induces remission in children with mild to moderate acute ulcerative colitis: A pilot study. Inflamm Bowel Dis, 15: 760–768. doi: 10.1002/ibd.20816
- Issue published online: 7 APR 2009
- Article first published online: 9 DEC 2008
- Manuscript Accepted: 12 OCT 2008
- Manuscript Received: 25 SEP 2008
- Stollery Children's Hospital Foundation
- therapeutic use;
- ulcerative colitis;
Background: Ulcerative colitis (UC) is a form of inflammatory bowel disease (IBD) that has periods of exacerbated symptoms and periods that are symptom-free. The treatment of active UC with probiotic bacteria could possibly induce remission. We evaluated the clinical efficacy and safety profile of probiotic preparation VSL#3 in the treatment of mild to moderate acute UC in the pediatric population.
Methods: Eighteen eligible patients between the ages of 3–17 with mild to moderate acute UC received open-label VSL#3 daily in 2 divided doses for 8 weeks. The disease activity pre- and post-VSL#3 therapy was assessed by the simple clinical colitis activity index (SCCAI); Mayo ulcerative colitis endoscopic score; inflammatory markers: erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP); serum cytokine profiling; and rectal tissue microbial profiling done at baseline and at week 8.
Results: Thirteen patients completed 8 weeks of VSL#3 treatment and 5 patients were withdrawn due to lack of improvement. Remission (defined as SCCAI ≤3) was achieved in 56% of children (n = 10); response (decrease in SCCAI ≥2, but final score ≤5) in 6% (n = 1); and no change or worsening in 39% (n = 7). Post-VSL#3 treatments demonstrated a bacterial taxonomy change in rectal biopsy. The VSL#3 was well tolerated in clinical trials and no biochemical and clinical adverse effects attributed to VSL#3 were identified.
Conclusions: Treatment of pediatric patients diagnosed with mild to moderate UC with VSL#3 resulted in a remission rate of 56% and a combined remission/response rate of 61%.
(Inflamm Bowel Dis 2008)